Nucleic acid vaccines for coronavirus

Abstract

Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses.

1 - 83 . (canceled) 
     
     
         84 . A pharmaceutical composition comprising a nucleic acid encoding an immunogenic fragment of the spike (S) protein of coronavirus SARS-CoV-2 and at least one lipid, wherein the immunogenic fragment comprises a sequence encoded by any one of SEQ ID NOS: 9, 11, 13 and 15, and wherein the at least one lipid comprises a cationic lipid. 
     
     
         85 . The pharmaceutical composition of  claim 84 , wherein the at least one lipid comprises between about 40 and about 50 mol percent of the cationic lipid. 
     
     
         86 . The pharmaceutical composition of  claim 84 , wherein the at least one lipid comprises the cationic lipid, DSPC, cholesterol, and a PEG-lipid. 
     
     
         87 . The pharmaceutical composition of  claim 84 , wherein the immunogenic fragment comprises the sequence encoded by SEQ ID NO: 9. 
     
     
         88 . The pharmaceutical composition of  claim 84 , wherein the immunogenic fragment comprises the sequence encoded by SEQ ID NO: 11. 
     
     
         89 . The pharmaceutical composition of  claim 84 , wherein the immunogenic fragment comprises the sequence encoded by SEQ ID NO: 13. 
     
     
         90 . The pharmaceutical composition of  claim 84 , wherein the immunogenic fragment comprises the sequence encoded by SEQ ID NO: 15. 
     
     
         91 . The pharmaceutical composition of  claim 84 , wherein the nucleic acid is an mRNA molecule. 
     
     
         92 . A method for treating, preventing or inhibiting an infectious disease in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition of  claim 84 . 
     
     
         93 . The method of  claim 92 , wherein the infectious disease is respiratory tract infection, lung infection, renal infection, liver infection, enteric infection, neurologic infections, respiratory syndrome, bronchitis, pneumonia, gastroenteritis, encephalomyelitis, encephalitis, sarcoidosis, diarrhea, hepatitis, or demyelinating disease. 
     
     
         94 . The method of  claim 92 , wherein the infectious disease is coronavirus disease 2019 (COVID-19). 
     
     
         95 . The method of  claim 92 , wherein the infectious disease is caused by SARS-CoV-2. 
     
     
         96 . A pharmaceutical composition comprising a nucleic acid encoding an immunogenic fragment of the spike (S) protein of coronavirus SARS-CoV-2 and at least one lipid, wherein the immunogenic fragment comprises a sequence set forth in any of one of SEQ ID NOS: 8, 10, 12 and 14, or a functional derivative thereof, and wherein the at least one lipid comprises a cationic lipid. 
     
     
         97 . The pharmaceutical composition of  claim 96 , wherein the at least one lipid comprises between about 40 and about 50 mol percent of the cationic lipid. 
     
     
         98 . The pharmaceutical composition of  claim 96 , wherein the at least one lipid comprises the cationic lipid, DSPC, cholesterol, and a PEG-lipid. 
     
     
         99 . The pharmaceutical composition of  claim 96 , wherein the immunogenic fragment comprises a sequence set forth in SEQ ID NO: 8 or a functional derivative thereof. 
     
     
         100 . The pharmaceutical composition of  claim 96 , wherein the immunogenic fragment comprises a sequence set forth in SEQ ID NO: 10 or a functional derivative thereof. 
     
     
         101 . The pharmaceutical composition of  claim 96 , wherein the immunogenic fragment comprises a sequence set forth in SEQ ID NO: 12 or a functional derivative thereof. 
     
     
         102 . The pharmaceutical composition of  claim 96 , wherein the immunogenic fragment comprises a sequence set forth in SEQ ID NO: 14 or a functional derivative thereof. 
     
     
         103 . The pharmaceutical composition of  claim 96 , wherein the nucleic acid is an mRNA molecule. 
     
     
         104 . A method for treating, preventing or inhibiting an infectious disease in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition of  claim 96 . 
     
     
         105 . The method of  claim 96 , wherein the infectious disease is respiratory tract infection, lung infection, renal infection, liver infection, enteric infection, neurologic infections, respiratory syndrome, bronchitis, pneumonia, gastroenteritis, encephalomyelitis, encephalitis, sarcoidosis, diarrhea, hepatitis, or demyelinating disease. 
     
     
         106 . The method of  claim 96 , wherein the infectious disease is coronavirus disease 2019 (COVID-19). 
     
     
         107 . The method of  claim 96 , wherein the infectious disease is caused by SARS-CoV-2. 
     
     
         108 . A pharmaceutical composition comprising a nucleic acid and at least one lipid, wherein the nucleic acid encodes an antigen comprising a continuous fragment of the spike (S) protein of coronavirus SARS-CoV-2 spanning amino acid residues 331 to 524, 319 to 541, 331 to 529 or 319 to 529, inclusive of the end points.